Core Viewpoint - The company, Boladeli, emphasizes the importance of original research in the pet pharmaceutical industry to enhance the reputation of domestic products in China [2]. Group 1: Company Achievements - Boladeli has been operating in the Taizhou Medical High-tech Industrial Development Zone since 2018, focusing on the research and production of innovative pet pharmaceuticals and functional health products [2]. - The company has received a total of 9 national new veterinary drug registration certificates, including 1 globally innovative Class I new veterinary drug and 4 nationally innovative Class II new veterinary drugs [2]. - In 2025 alone, Boladeli achieved a record of obtaining 5 new veterinary drug registration certificates [2]. - Over 17 additional products are currently in the new veterinary drug registration process, with more than half being globally and domestically original innovations [2]. Group 2: Product Innovations - The "Miao Bei Hu" cat trivalent vaccine, China's first approved Class II new veterinary drug, utilizes local prevalent strains and advanced production techniques to enhance safety [3]. - The "Miao Bei Jian" recombinant cat interferon is the first approved in China and the second globally, designed for both injection and eye drop use, marking significant progress in pet gene engineering drug development in China [3]. Group 3: Industry Context - The pet medical market in China is rapidly expanding due to the increasing role of pets in families, leading to a growing demand for safe, reliable, and sustainably supplied domestic drugs and vaccines [2]. - Boladeli's investment of over 200 million yuan in building a comprehensive R&D and production base in accordance with EU standards reflects its commitment to accelerating the industrialization of new products [3][4]. - The ongoing growth of the pet economy is attributed to the deepening emotional connection between humans and pets, with Boladeli aiming to provide high-quality domestic pet pharmaceuticals [4].

Core Viewpoint - The article highlights the development and success of the China Medical City in Taizhou, which has become a significant hub for the biopharmaceutical industry in China, attracting numerous enterprises and fostering innovation in vaccine and medical device research and development [4][5][10]. Group 1: Industry Development - Established in May 2009, the China Medical City is the only national-level high-tech zone in China focused on the pharmaceutical and health industry [5]. - The city has positioned itself as a leader in the biopharmaceutical sector, particularly in vaccine, antibody, and in vitro diagnostic reagent research, differentiating itself from other regions like Shanghai and Suzhou [5][6]. - The city has built the largest vaccine factory center in Jiangsu Province, with over 50 vaccine products in production or research, and has successfully incubated more than 50 enterprises, including 5 listed companies [6][10]. Group 2: Financial Support - In just a few years, the park has nurtured 9 biopharmaceutical companies that have successfully gone public, with 18 more in the pipeline for IPO [7][8]. - The local investment platform, Huayin Financial Investment Co., has invested over 1.2 billion yuan in the park's industries, providing essential financial support to meet the specific needs of biopharmaceutical companies [8][9]. - The financial ecosystem in Taizhou includes various models such as "incubation + angel investment" and "venture capital + insurance," creating a "capital rainforest" that offers tailored financial services to enterprises [9]. Group 3: Comprehensive Services - The China Medical City has developed a complete service chain to support innovation, including preclinical research, clinical trials, and regulatory approval processes, significantly reducing communication costs for enterprises [10][11]. - The establishment of the first drug supervision service complex in China has streamlined the approval process, providing integrated services for drug registration and policy interpretation [11]. - The city has attracted over 50,000 talents, including 4,600 high-level professionals, enhancing its innovation capabilities and supporting the growth of local enterprises [11].